80 related articles for article (PubMed ID: 18318249)
21. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
22. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.
Oh HM; Ng AW; Lee SK
Singapore Med J; 1996 Jun; 37(3):255-7. PubMed ID: 8942221
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia. Italian Ciprofloxacin Study Group.
Periti P; Mazzei T; Curti ME
Int J Antimicrob Agents; 1998 Aug; 10(3):215-22. PubMed ID: 9832282
[TBL] [Abstract][Full Text] [Related]
24. Importance of atypical pathogens of community-acquired pneumonia.
Plouffe JF
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
[TBL] [Abstract][Full Text] [Related]
25. Atypical bacterial pathogens in community-acquired pneumonia in children: a hospital-based study.
Agarwal J; Awasthi S; Rajput A; Tiwari M; Jain A
Trop Doct; 2009 Apr; 39(2):109-11. PubMed ID: 19299299
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of ciprofloxacin with biapenem in patients with moderate or severe pneumonia].
Rikimaru T; Yonemitu J; Koga T; Shimada A; Yokoyama T; Kawayama T; Kamimura T; Aizawa H
Kansenshogaku Zasshi; 2007 May; 81(3):276-83. PubMed ID: 17564116
[TBL] [Abstract][Full Text] [Related]
27. [Results of survey of adult community-acquired pneumonia utilizing flow chart of diagnostic guideline for management of respiratory infections].
Watanabe A; Matsushima T; Kohno S; Abe S; Aoki N; Kubo K; Sugiyama Y; Kikuchi N; Kudou S; Ishigatsubo Y; Shimokata K; Hirata K; Tohda Y; Narita N; Ueda N; Niki Y; Nasu M; Saitou A
Nihon Kokyuki Gakkai Zasshi; 2003 Nov; 41(11):781-96. PubMed ID: 14661550
[TBL] [Abstract][Full Text] [Related]
28. Mycoplasma Pneumoniae infection in Malaysian children admitted with community acquired pneumonia.
Chan PW; Lum LC; Ngeow YF; Yasim MY
Southeast Asian J Trop Med Public Health; 2001 Jun; 32(2):397-401. PubMed ID: 11556595
[TBL] [Abstract][Full Text] [Related]
29. Clinical end points of therapy for patients with mild community-acquired pneumonia.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S140-4. PubMed ID: 18986280
[TBL] [Abstract][Full Text] [Related]
30. Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS "curb" index to assess severity.
Loh LC
Med J Malaysia; 2006 Mar; 61(1):128-30. PubMed ID: 16708753
[No Abstract] [Full Text] [Related]
31. Bronchoalveolar interleukin-1 beta: a marker of bacterial burden in mechanically ventilated patients with community-acquired pneumonia.
Wu CL; Lee YL; Chang KM; Chang GC; King SL; Chiang CD; Niederman MS
Crit Care Med; 2003 Mar; 31(3):812-7. PubMed ID: 12626989
[TBL] [Abstract][Full Text] [Related]
32. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
[TBL] [Abstract][Full Text] [Related]
33. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool.
Buising KL; Thursky KA; Black JF; MacGregor L; Street AC; Kennedy MP; Brown GV
Emerg Med Australas; 2007 Oct; 19(5):418-26. PubMed ID: 17919214
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization.
Rosón B; Carratalà J; Verdaguer R; Dorca J; Manresa F; Gudiol F
Clin Infect Dis; 2000 Oct; 31(4):869-74. PubMed ID: 11049763
[TBL] [Abstract][Full Text] [Related]
35. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.
Bakker-Woudenberg IA; ten Kate MT; Guo L; Working P; Mouton JW
Antimicrob Agents Chemother; 2001 May; 45(5):1487-92. PubMed ID: 11302815
[TBL] [Abstract][Full Text] [Related]
36. [Community-acquired pneumonia: considerations on ambulatory management].
Zanetti G
Schweiz Med Wochenschr; 1997 Mar; 127(13):528-34. PubMed ID: 9190664
[TBL] [Abstract][Full Text] [Related]
37. The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections.
Ohmichi M; Hiraga Y
J Int Med Res; 1999; 27(6):297-304. PubMed ID: 10726239
[TBL] [Abstract][Full Text] [Related]
38. Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study.
Welte T; Dellinger RP; Ebelt H; Ferrer M; Opal SM; Schliephake DE; Wartenberg-Demand A; Werdan K; Löffler K; Torres A
Respir Med; 2015 Jun; 109(6):758-67. PubMed ID: 25887136
[TBL] [Abstract][Full Text] [Related]
39. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects.
Chono S; Tanino T; Seki T; Morimoto K
Drug Dev Ind Pharm; 2008 Oct; 34(10):1090-6. PubMed ID: 18777242
[TBL] [Abstract][Full Text] [Related]
40. [Clinical effect of continuous infusion of meropenem on bacterial pneumonia in the elderly].
Okimoto N; Kibayashi T; Mimura K; Yamato K; Kurihara T; Honda Y; Osaki K; Asaoka N; Ohba H
Nihon Kokyuki Gakkai Zasshi; 2006 Jun; 44(6):431-5. PubMed ID: 16841713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
